MK-677 safety warnings: what the evidence actually says

What did @j_sargio actually say?

The creator ran through five reasons to avoid MK-677, which they called a "psalm" (likely meaning SARM, though MK-677 is technically a ghrelin mimetic, not a SARM). Their claims: it disrupts hormone balance by "replicating gramin" and shutting down natural GH, it produces only water weight gains that disappear after stopping, long-term effects are unstudied, it increases insulin sensitivity in a way that causes diabetes, and it drives unhealthy appetite and fat gain. Some of these points have real scientific grounding. Others are garbled, reversed, or just wrong.

It's worth noting the creator mislabels MK-677 as a SARM throughout. MK-677 (ibutamoren) is an oral ghrelin receptor agonist that stimulates GH secretion. That distinction matters when evaluating the claims, because the mechanism drives what actually happens in the body.

Does the science back this up?

Partially. The strongest claim here is also the least discussed one: long-term safety data genuinely does not exist in healthy adults seeking body composition changes. A 2008 trial by Nass et al. in the Annals of Internal Medicine studied MK-677 in older adults with GH deficiency over two years and found meaningful GH and IGF-1 increases, but also noted adverse effects including increased fasting glucose and insulin resistance. That trial is often cited as evidence MK-677 works, but it also flags metabolic concerns that the creator got partially right, though they described them backwards.

On the water retention claim, yes, early gains from MK-677 are substantially water and glycogen. Studies including the Nass 2008 trial showed increases in fat-free mass, but separating lean tissue from water is complicated. The creator's broader point that users mistake water retention for muscle gain has support in anecdotal and clinical contexts alike.

What did they get wrong, and what did they get right?

The biggest factual error is the insulin sensitivity claim. The creator says MK-677 "increases insulin sensitivity" and calls this dangerous. That is backwards. The documented concern with MK-677 is that it can increase insulin resistance and raise fasting glucose, not improve sensitivity. Nass et al. 2008 found statistically significant increases in fasting blood glucose. Murphy et al. 1998 in the Journal of Clinical Endocrinology and Metabolism also noted transient insulin resistance. Saying it increases insulin sensitivity is the opposite of what the evidence shows, and the direction of the error matters clinically.

The "ghrelin shuts down your own GH" claim is also oversimplified. MK-677 stimulates GH release through ghrelin receptor agonism. It does not necessarily suppress endogenous GH the way exogenous GH might via negative feedback. Some suppression of natural ghrelin signaling is plausible, but the mechanism described is muddled. Credit where it's due: the long-term data point and the appetite and fat gain warning are both legitimate concerns worth raising.

What should you actually know?

MK-677 occupies a strange regulatory space. It is not FDA-approved for any indication in healthy adults. It has been studied clinically, mostly in older populations or people with GH deficiency, not in young gym-goers. The metabolic signals from those trials are not encouraging: elevated fasting glucose, increased insulin resistance, and possible edema are documented findings, not fringe concerns.

The appetite increase the creator mentions is by design. Ghrelin is the hunger hormone, and agonizing its receptor makes people eat more. Whether that leads to fat gain depends entirely on whether someone is eating in a caloric surplus. It is not inherently dangerous, but it is not a free muscle-building signal either.

The compounded versions circulating in wellness markets are not equivalent to clinical-grade compounds studied in trials. Anyone considering MK-677 through a telehealth platform should have a real conversation about their metabolic baseline, fasting glucose, and goals before proceeding.